ArticleImmunity2018
Immune Checkpoint Blockade across the Cancer Care Continuum.
Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07072325 (A Clinical Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Head & Neck Cancers), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Head & Neck Cancers
Who cites it
20 citing papers in PubMed.
- Neutrophil depletion dampens inflammation and enhances CD8Translational cancer research · 2025Article
- Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors.Journal for immunotherapy of cancer · 2025Article
- Conventional type 1 dendritic cells (cDC1) in cancer immunity.Biology direct · 2023Review
- Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.Endocrine · 2023Article
- Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment.Science advances · 2023Article
- Recent advances in 2D material-based phototherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma.Pharmaceutics · 2022Article
- Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8Cellular oncology (Dordrecht, Netherlands) · 2021Article
- Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.EMBO molecular medicine · 2021Review
- Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma.International journal of molecular sciences · 2021Review
- Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.Nature communications · 2021Article
- Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy.Frontiers in immunology · 2021Review
- Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.Journal of clinical medicine · 2020Review
- Understanding genomics and the immune environment of penile cancer to improve therapy.Nature reviews. Urology · 2020Review
- NK Cell-Based Immune Checkpoint Inhibition.Frontiers in immunology · 2020Review
- Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis.BMJ case reports · 2019Article
- Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.Nature communications · 2019Article
- Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?The Prostate · 2019Article
- Modulating the microbiome to improve therapeutic response in cancer.The Lancet. Oncology · 2019Review
- Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment.Frontiers in oncology · 2019Review
Corrections and comments
- Comment on
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to-or in place of-standard front-line therapy.
Indexed as
Identifiers
29924973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.